Compare HIHO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIHO | KALA |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.4M |
| IPO Year | 2002 | 2017 |
| Metric | HIHO | KALA |
|---|---|---|
| Price | $0.85 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 283.3K |
| Earning Date | 12-14-2026 | 11-23-2026 |
| Dividend Yield | ★ 11.83% | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.07 |
| 52 Week High | $2.21 | $191.00 |
| Indicator | HIHO | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 54.13 | 31.06 |
| Support Level | $0.74 | $0.11 |
| Resistance Level | $0.93 | $0.35 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 67.58 | 10.14 |
Highway Holdings Ltd manufactures and sells metal, plastic and electronic parts, components, subassemblies and finished products for OEMs and contract manufacturers. Its products are used in photocopiers, laser printers, print cartridges, electrical connectors, electrical circuits and other applications. The Company also offers tooling design and development, metal stamping, screen printing, plastic injection molding, pad printing and electronic assembly of printed circuit boards. It operates through metal stamping and mechanical OEM manufacturing operations and electronic OEM manufacturing operations, with metal stamping and mechanical OEM manufacturing operations generating maximum revenue. The Company generates maximum revenue from Europe.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.